Chardan Capital Markets
http://www.chardancm.comChardan Capital Markets is an international investment bank headquartered in New York City, with offices in Los Angeles and Beijing. Chardan provides a wide array of financial services including investment banking, capital markets, international trading and equity research. The investment banking group focuses on providing banking and advisory services to private and public companies in small and mid-cap markets. The institutional coverage of Chardan Capital Markets spans North America, Europe and Asia. Chardan Capital Markets LLC is a registered broker-dealer with the U.S. Securities and Exchange Commission and is a member of the following: Financial Industry Regulatory Authority (FINRA); Municipal Securities Rulemaking Board (MSRB); Securities Insurance Protection Corporation (SIPC); NASDAQ Stock Market and the NYSE Arca, Inc.
View Older Stories View More Recent Stories
-
Chardan Capital Markets Reiterates Buy on uniQure (QURE) Following New FDA Guidelines on Gene Therapy
-
Castlight Health to Participate in Upcoming Investor Conferences
-
DarioHealth to Present at Chardan's Digital Health Conference
-
VectoIQ Acquisition Corp. Closes $200 Million Initial Public Offering
-
Tabula Rasa Healthcare (TRHC) PT Raised to $68 at Chardan Capital Markets
-
VectoIQ Acquisition Corp. (VITQ) Prices 20M Unit IPO at $10/Unit
-
VectoIQ Acquisition Corp. Announces Pricing of $200 Million Initial Public Offering
-
Pre-Open Movers 05/15: (XENE) (PFNX) (SORL) Higher; (VIPS) (MYE) (TSLA) Lower (more...)
-
Adherium to Present at the Chardan Digital Health Conference on Tuesday, May 22, 2018
-
Adherium to Present at the Chardan Digital Health Conference on Tuesday, May 22, 2018
-
UPDATE: Chardan Capital Markets Upgrades Intellia Therapeutics (NTLA) to Buy
-
Editas Medicine (EDIT) PT Lowered to $55 at Chardan Capital Markets
-
CRISPR Therapeutics (CRSP) PT Raised to $72.50 at Chardan Capital Markets 'on the Chardan Gene Editing Framework'
-
Profire Energy (PFIE) PT Raised to $5 at Chardan Capital Markets
-
Castlight Health Inc. (CSLT) PT Raised to $6 at Chardan Capital Markets
-
Arrowhead Research (ARWR) PT Raised to $9.50 at Chardan Capital Markets
-
uniQure Announces Closing Of Public Offering And Full Exercise Of The Underwriters' Option To Purchase Additional Shares
-
Chardan Capital Markets Reiterates Buy on 22nd Century Group (XXII)
-
Smith Micro Software (SMSI) Announces $7M Private Placement Offering of Common Stock and Warrants
-
Smith Micro Announces Above Market $7.0 Million Private Placement Offering of Common Stock and Warrants
-
uniQure (QURE) Prices 4.5M Share Offering at $28.50/Sh
-
uniQure Announces Pricing of its Public Offering
-
SRAX to Present at Upcoming Investment Conferences
-
Teladoc (TDOC) PT Raised to $57 at Chardan Capital Markets
-
Tivity Health (TVTY) PT Raised to $42 at Chardan Capital Markets
-
Chardan Capital Markets Downgrades Spark Therapeutics (ONCE) to Neutral
-
PlacementTracker Publishes Q1 2018 PIPE and Private Placement Markets League Tables
-
Chardan Capital Markets Downgrades AveXis (AVXS) to Neutral Pending Takeover
-
Chardan Capital Markets Downgrades Assembly Biosciences (ASMB) to Neutral; 'CpAM data are promising but undifferentiated'
-
BrainStorm Cell Therapeutics to Present at ARM's 6th Annual Cell & Gene Therapy Investor Day, April 17 in New York
-
Tiberius Acquisition Corporation Common Stock And Warrants To Commence Trading Separately On April 10, 2018
-
Regenxbio Inc. (RGNX) PT Raised to $90 at Chardan Capital Markets on Novartis-AveXis; Could Also Become a Target
-
AveXis (AVXS) PT Raised to $218 at Chardan Capital Markets
-
Chardan Capital Markets Starts DarioHealth (DRIO) at Buy
-
Chardan Capital Markets Starts ProQR Therapeutics N.V. (PRQR) at Buy
-
Biocept (BIOC) PT Lowered to $0.65 at Chardan Capital Markets
-
OncoCyte Announces the Closing of a $10 Million Private Placement of Common Stock
-
Tiberius Acquisition Corporation Announces Closing of Underwriters' Full Over-Allotment Option in Connection with its Initial Public Offering
-
The Alliance for Regenerative Medicine Releases Complete Agenda for Sixth Annual Cell & Gene Therapy Investor Day
-
The Alliance for Regenerative Medicine Releases Complete Agenda for Sixth Annual Cell & Gene Therapy Investor Day
-
Esperion Therapeutics (ESPR) PT Raised to $100 at Chardan Capital Markets
-
Spark Therapeutics (ONCE) PT Raised to $80 at Chardan Capital Markets
-
Caladrius Biosciences (CLBS) PT Raised to $7 at Chardan Capital Markets
-
Tiberius Acquisition Corporation Announces Closing of $150,000,000 Initial Public Offering
-
Vuzix Corp. (VUZI) PT Maintained at $10 at Chardan Capital Markets; 'Positioned for Break-Out Year'
-
HealthEquity, Inc (HQY) PT Raised to $77 at Chardan Capital Markets
-
Chardan Capital Markets Resumes Arbutus Biopharma (ABUS) at Buy
-
Tabula Rasa Healthcare (TRHC) PT Raised to $50 at Chardan Capital Markets
-
Tiberius Acquisition Corp (TIBR) Prices 15M Share IPO at $10/Sh
-
Tiberius Acquisition Corporation Announces Pricing of $150,000,000 Initial Public Offering

